{"pmid":32238585,"title":"Isolation and full-length genome characterization of SARS-CoV-2 from COVID-19 cases in Northern Italy.","text":["Isolation and full-length genome characterization of SARS-CoV-2 from COVID-19 cases in Northern Italy.","In December 2019, the novel coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2 emerged in the city of Wuhan in the Hubei province, People's Republic of China, as the etiologic agent of coronavirus disease 2019 (COVID-19), which has hence spread worldwide causing a global pandemic (1-3).....","J Virol","Licastro, Danilo","Rajasekharan, Sreejith","Dal Monego, Simeone","Segat, Ludovica","D'Agaro, Pierlanfranco","Marcello, Alessandro","32238585"],"abstract":["In December 2019, the novel coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2 emerged in the city of Wuhan in the Hubei province, People's Republic of China, as the etiologic agent of coronavirus disease 2019 (COVID-19), which has hence spread worldwide causing a global pandemic (1-3)....."],"journal":"J Virol","authors":["Licastro, Danilo","Rajasekharan, Sreejith","Dal Monego, Simeone","Segat, Ludovica","D'Agaro, Pierlanfranco","Marcello, Alessandro"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238585","week":"202014|Mar 30 - Apr 05","doi":"10.1128/JVI.00543-20","source":"PubMed","locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1662996001595588608,"score":7.6048946,"similar":[{"pmid":32132184,"title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.","text":["Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.","Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome-coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2) that is causing the serious coronavirus disease 2019 (COVID-19) epidemic. Here, we present cryo-electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B(0)AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein (S protein) of SARS-CoV-2, both at an overall resolution of 2.9 angstroms, with a local resolution of 3.5 angstroms at the ACE2-RBD interface. The ACE2-B(0)AT1 complex is assembled as a dimer of heterodimers, with the collectrin-like domain of ACE2 mediating homodimerization. The RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues. These findings provide important insights into the molecular basis for coronavirus recognition and infection.","Science","Yan, Renhong","Zhang, Yuanyuan","Li, Yaning","Xia, Lu","Guo, Yingying","Zhou, Qiang","32132184"],"abstract":["Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome-coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2) that is causing the serious coronavirus disease 2019 (COVID-19) epidemic. Here, we present cryo-electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B(0)AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein (S protein) of SARS-CoV-2, both at an overall resolution of 2.9 angstroms, with a local resolution of 3.5 angstroms at the ACE2-RBD interface. The ACE2-B(0)AT1 complex is assembled as a dimer of heterodimers, with the collectrin-like domain of ACE2 mediating homodimerization. The RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues. These findings provide important insights into the molecular basis for coronavirus recognition and infection."],"journal":"Science","authors":["Yan, Renhong","Zhang, Yuanyuan","Li, Yaning","Xia, Lu","Guo, Yingying","Zhou, Qiang"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32132184","week":"202010|Mar 02 - Mar 08","doi":"10.1126/science.abb2762","source":"PubMed","locations":["ACE2-RBD"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663095626069442562,"score":98.68754},{"pmid":32175703,"title":"COVID-19 in the Shadows of MERS-CoV in the Kingdom of Saudi Arabia.","text":["COVID-19 in the Shadows of MERS-CoV in the Kingdom of Saudi Arabia.","Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has plagued the Middle East since it was first reported in 2012. Recently, at the end of December 2019, a cluster of pneumonia cases were reported from Wuhan city, Hubei Province, China, linked to a wet seafood market with a new coronavirus identified as the etiologic agent currently named SARS-CoV-2. Most cases are in Mainland China with international spread to 25 countries. The novelty of the virus, the rapid national and international spread, and the lack of therapeutic and preventative strategies have led the WHO International Health Regulation emergency committee to declare the disease as Public Health Emergency of International Concern (PHEIC) on January 30, 2020. As it relates to countries with the ongoing MERS-CoV community cases and hospital acquired infections, there will be a huge challenge for HCWs to deal with both coronaviruses, especially with the lack of standardized and approved point of care testing. This challenge will now be faced by the whole global health community dealing with COVID-19 since both coronaviruses have similar presentation. Those patients should now be tested for both MERS-CoV and SARS-CoV-2 simultaneously, and with the continuing wide international spread of SARS-CoV-2, the travel history to China in the last 14 days will be of less significance.","J Epidemiol Glob Health","Barry, Mazin","Al Amri, Maha","Memish, Ziad A","32175703"],"abstract":["Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has plagued the Middle East since it was first reported in 2012. Recently, at the end of December 2019, a cluster of pneumonia cases were reported from Wuhan city, Hubei Province, China, linked to a wet seafood market with a new coronavirus identified as the etiologic agent currently named SARS-CoV-2. Most cases are in Mainland China with international spread to 25 countries. The novelty of the virus, the rapid national and international spread, and the lack of therapeutic and preventative strategies have led the WHO International Health Regulation emergency committee to declare the disease as Public Health Emergency of International Concern (PHEIC) on January 30, 2020. As it relates to countries with the ongoing MERS-CoV community cases and hospital acquired infections, there will be a huge challenge for HCWs to deal with both coronaviruses, especially with the lack of standardized and approved point of care testing. This challenge will now be faced by the whole global health community dealing with COVID-19 since both coronaviruses have similar presentation. Those patients should now be tested for both MERS-CoV and SARS-CoV-2 simultaneously, and with the continuing wide international spread of SARS-CoV-2, the travel history to China in the last 14 days will be of less significance."],"journal":"J Epidemiol Glob Health","authors":["Barry, Mazin","Al Amri, Maha","Memish, Ziad A"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32175703","week":"202012|Mar 16 - Mar 22","doi":"10.2991/jegh.k.200218.003","keywords":["*COVID-19","*MERS-CoV","*SARS-CoV-2","*Saudi Arabia"],"source":"PubMed","locations":["China","Hubei","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1662334543606054912,"score":95.33019},{"pmid":32112977,"pmcid":"PMC7105032","title":"World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).","text":["World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).","An unprecedented outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus was identified as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is caused by a betacoronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with 90,870 laboratory-confirmed cases and over 3,000 deaths worldwide. In response to this global outbreak, we summarise the current state of knowledge surrounding COVID-19.","Int J Surg","Sohrabi, Catrin","Alsafi, Zaid","O'Neill, Niamh","Khan, Mehdi","Kerwan, Ahmed","Al-Jabir, Ahmed","Iosifidis, Christos","Agha, Riaz","32112977"],"abstract":["An unprecedented outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus was identified as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is caused by a betacoronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with 90,870 laboratory-confirmed cases and over 3,000 deaths worldwide. In response to this global outbreak, we summarise the current state of knowledge surrounding COVID-19."],"journal":"Int J Surg","authors":["Sohrabi, Catrin","Alsafi, Zaid","O'Neill, Niamh","Khan, Mehdi","Kerwan, Ahmed","Al-Jabir, Ahmed","Iosifidis, Christos","Agha, Riaz"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32112977","week":"20209|Feb 24 - Mar 01","doi":"10.1016/j.ijsu.2020.02.034","keywords":["COVID-19","Global health emergency","Novel coronavirus","Viral transmission","Wuhan"],"source":"PubMed","locations":["China","Hubei","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission","Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1663095626114531328,"score":88.57556},{"pmid":32243729,"title":"The isolation period should be longer: Lesson from a child infected with SARS-CoV-2 in Chongqing, China.","text":["The isolation period should be longer: Lesson from a child infected with SARS-CoV-2 in Chongqing, China.","In December 2019, COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbroke in Wuhan, the capital city of Hubei province, China. The disease rapidly spread to other areas in China due to a huge population movement during the New Year Festival. Here, a 7-year-old child with SARS-CoV-2 infection in Chongqing, outside of Wuhan, Hubei province, was reported. This case suggested that children infected with SARS-CoV-2 are more likely to present milder manifestations than adults. The continuous positive real-time reverse transcription-polymerase chain reaction assay for SARS-CoV-2 in the child's throat swab sample indicated the isolation period for suspected child cases should be longer than 14 days.","Pediatr Pulmonol","Lin, Jilei","Duan, Jun","Tan, Tingdan","Fu, Zhou","Dai, Jihong","32243729"],"abstract":["In December 2019, COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbroke in Wuhan, the capital city of Hubei province, China. The disease rapidly spread to other areas in China due to a huge population movement during the New Year Festival. Here, a 7-year-old child with SARS-CoV-2 infection in Chongqing, outside of Wuhan, Hubei province, was reported. This case suggested that children infected with SARS-CoV-2 are more likely to present milder manifestations than adults. The continuous positive real-time reverse transcription-polymerase chain reaction assay for SARS-CoV-2 in the child's throat swab sample indicated the isolation period for suspected child cases should be longer than 14 days."],"journal":"Pediatr Pulmonol","authors":["Lin, Jilei","Duan, Jun","Tan, Tingdan","Fu, Zhou","Dai, Jihong"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243729","week":"202014|Mar 30 - Apr 05","doi":"10.1002/ppul.24763","source":"PubMed","locations":["Wuhan","China","Chongqing","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1663079112845033474,"score":87.56145},{"pmid":32238757,"title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","text":["Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.","J Microbiol Biotechnol","Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun","32238757"],"abstract":["Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19."],"journal":"J Microbiol Biotechnol","authors":["Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238757","week":"202014|Mar 30 - Apr 05","doi":"10.4014/jmb.2003.03011","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","coronavirus","outbreak"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1662996001610268672,"score":87.0512}]}